Investigational drug · Phase 3
Enlituo
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Enlituo"
First trial start
2026
May 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Enlituo", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Approved drugs for the same conditions: Colorectal cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Enlituo" as an intervention, largest first.
- Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.Pivotal-lookingRecruiting
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT07595276 · 608 participants (planned) · Start May 27, 2026 · Primary completion Oct 1, 2029
Drug: Enlituo®; Erbitux® · For: Colorectal Cancer
Sites: Guangzhou, China
- A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.Pivotal-lookingRecruiting
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT07791745 · 362 participants (planned) · Start Sep 16, 2026 · Primary completion Aug 30, 2032
Drug: Enlituo® + Anyouping® + PBC; Placebo-Enlituo + Anyouping® + PBC · For: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Sites: Shanghai, China
PfizerPfizer (PFE)
NCT07318805 · 260 participants (planned) · Start Dec 23, 2025 · Primary completion Apr 14, 2029
Drug: PF-08032562; Fulvestrant and 5 more · For: Advanced Breast Cancer; Metastatic Breast Cancer (HR+/ HER2-); Colorectal Cancer and 2 more
Sites: Duarte, California; Grand Rapids, Michigan; Long Island City, New York · 17 sites in all
- Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male VolunteersCompleted
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT07246291 · 86 participants · Start Nov 11, 2025 · Primary completion Apr 14, 2026
Drug: New technology Enlituo; Approved technology Enlituo · For: Healthy Adult Male
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.